S&P 500   3,136.52 (+0.02%)
DOW   27,898.36 (-0.04%)
QQQ   204.35 (+0.14%)
AAPL   269.15 (+0.84%)
FB   200.78 (-0.28%)
MSFT   151.72 (+0.24%)
GOOGL   1,341.79 (-0.09%)
AMZN   1,741.63 (-0.45%)
CGC   20.67 (-2.91%)
NVDA   215.25 (+1.45%)
MU   47.83 (+2.97%)
BABA   201.80 (+1.54%)
GE   11.01 (+0.18%)
TSLA   348.22 (+2.56%)
T   38.23 (+0.50%)
AMD   39.63 (+1.80%)
ACB   2.56 (-2.29%)
F   9.07 (+0.55%)
NFLX   297.51 (-1.65%)
BAC   33.49 (-0.06%)
GILD   66.72 (-0.31%)
DIS   146.55 (+0.23%)
S&P 500   3,136.52 (+0.02%)
DOW   27,898.36 (-0.04%)
QQQ   204.35 (+0.14%)
AAPL   269.15 (+0.84%)
FB   200.78 (-0.28%)
MSFT   151.72 (+0.24%)
GOOGL   1,341.79 (-0.09%)
AMZN   1,741.63 (-0.45%)
CGC   20.67 (-2.91%)
NVDA   215.25 (+1.45%)
MU   47.83 (+2.97%)
BABA   201.80 (+1.54%)
GE   11.01 (+0.18%)
TSLA   348.22 (+2.56%)
T   38.23 (+0.50%)
AMD   39.63 (+1.80%)
ACB   2.56 (-2.29%)
F   9.07 (+0.55%)
NFLX   297.51 (-1.65%)
BAC   33.49 (-0.06%)
GILD   66.72 (-0.31%)
DIS   146.55 (+0.23%)
S&P 500   3,136.52 (+0.02%)
DOW   27,898.36 (-0.04%)
QQQ   204.35 (+0.14%)
AAPL   269.15 (+0.84%)
FB   200.78 (-0.28%)
MSFT   151.72 (+0.24%)
GOOGL   1,341.79 (-0.09%)
AMZN   1,741.63 (-0.45%)
CGC   20.67 (-2.91%)
NVDA   215.25 (+1.45%)
MU   47.83 (+2.97%)
BABA   201.80 (+1.54%)
GE   11.01 (+0.18%)
TSLA   348.22 (+2.56%)
T   38.23 (+0.50%)
AMD   39.63 (+1.80%)
ACB   2.56 (-2.29%)
F   9.07 (+0.55%)
NFLX   297.51 (-1.65%)
BAC   33.49 (-0.06%)
GILD   66.72 (-0.31%)
DIS   146.55 (+0.23%)
S&P 500   3,136.52 (+0.02%)
DOW   27,898.36 (-0.04%)
QQQ   204.35 (+0.14%)
AAPL   269.15 (+0.84%)
FB   200.78 (-0.28%)
MSFT   151.72 (+0.24%)
GOOGL   1,341.79 (-0.09%)
AMZN   1,741.63 (-0.45%)
CGC   20.67 (-2.91%)
NVDA   215.25 (+1.45%)
MU   47.83 (+2.97%)
BABA   201.80 (+1.54%)
GE   11.01 (+0.18%)
TSLA   348.22 (+2.56%)
T   38.23 (+0.50%)
AMD   39.63 (+1.80%)
ACB   2.56 (-2.29%)
F   9.07 (+0.55%)
NFLX   297.51 (-1.65%)
BAC   33.49 (-0.06%)
GILD   66.72 (-0.31%)
DIS   146.55 (+0.23%)
Log in

NASDAQ:JNCE - Jounce Therapeutics Stock Price, Forecast & News

$8.17
+0.04 (+0.49 %)
(As of 12/10/2019 12:02 PM ET)
Today's Range
$7.93
Now: $8.17
$8.42
50-Day Range
$3.48
MA: $4.92
$8.11
52-Week Range
$2.66
Now: $8.17
$9.80
Volume359,256 shs
Average Volume1.07 million shs
Market Capitalization$271.49 million
P/E RatioN/A
Dividend YieldN/A
Beta3.73
Jounce Therapeutics, Inc, a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company offers vopratelimab, a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors, which is in Phase I/II clinical trial for the treatment of head and neck squamous cell cancer, non-small cell lung cancer, triple negative breast cancer, gastric cancer, and other tumor types identified through its translational science platform. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:JNCE
CUSIPN/A
Phone857-259-3840

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$65.20 million
Book Value$3.18 per share

Profitability

Net Income$-27,380,000.00

Miscellaneous

Employees115
Market Cap$271.49 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive JNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for JNCE and its competitors with MarketBeat's FREE daily newsletter.


Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics Inc (NASDAQ:JNCE) released its earnings results on Thursday, November, 7th. The company reported $2.90 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $2.24 by $0.66. The firm earned $119.45 million during the quarter, compared to analysts' expectations of $99.97 million. Jounce Therapeutics had a net margin of 46.11% and a return on equity of 64.54%. View Jounce Therapeutics' Earnings History.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Jounce Therapeutics.

What is the consensus analysts' recommendation for Jounce Therapeutics?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Jounce Therapeutics.

Has Jounce Therapeutics been receiving favorable news coverage?

News headlines about JNCE stock have trended somewhat positive this week, InfoTrie reports. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Jounce Therapeutics earned a coverage optimism score of 1.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Jounce Therapeutics.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totalling 425,400 shares, an increase of 40.9% from the September 15th total of 302,000 shares. Based on an average trading volume of 125,200 shares, the short-interest ratio is presently 3.4 days. Currently, 2.8% of the company's shares are short sold. View Jounce Therapeutics' Current Options Chain.

Who are some of Jounce Therapeutics' key competitors?

What other stocks do shareholders of Jounce Therapeutics own?

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the folowing people:
  • Dr. Richard Murray, Pres, CEO & Director (Age 60)
  • Mr. Hugh M. Cole, Chief Bus. Officer & Head of Corp. Devel. (Age 54)
  • Dr. Elizabeth G. Tréhu, Chief Medical Officer (Age 59)
  • Dr. James P. Allison, Founder
  • Dr. Thomas F. Gajewski, Founder

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (1.27%), Millennium Management LLC (0.48%), Strs Ohio (0.47%), Granahan Investment Management Inc. MA (0.37%), Essex Investment Management Co. LLC (0.33%) and Russell Investments Group Ltd. (0.10%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, Kimberlee C Drapkin and Richard /Ca/ Murray. View Institutional Ownership Trends for Jounce Therapeutics.

Which institutional investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including Barclays PLC. Company insiders that have sold Jounce Therapeutics company stock in the last year include Hugh M Cole and Kimberlee C Drapkin. View Insider Buying and Selling for Jounce Therapeutics.

Which institutional investors are buying Jounce Therapeutics stock?

JNCE stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Essex Investment Management Co. LLC, Strs Ohio, State Street Corp, Russell Investments Group Ltd., Meeder Asset Management Inc., Tower Research Capital LLC TRC and Granahan Investment Management Inc. MA. View Insider Buying and Selling for Jounce Therapeutics.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $8.17.

How big of a company is Jounce Therapeutics?

Jounce Therapeutics has a market capitalization of $271.49 million and generates $65.20 million in revenue each year. The company earns $-27,380,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis. Jounce Therapeutics employs 115 workers across the globe.View Additional Information About Jounce Therapeutics.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is http://www.jouncetx.com/.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3840.


MarketBeat Community Rating for Jounce Therapeutics (NASDAQ JNCE)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  224 (Vote Outperform)
Underperform Votes:  194 (Vote Underperform)
Total Votes:  418
MarketBeat's community ratings are surveys of what our community members think about Jounce Therapeutics and other stocks. Vote "Outperform" if you believe JNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel